These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Rationale and design of the enoximone clinical trials program. Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960 [TBL] [Abstract][Full Text] [Related]
27. Cardiac inotropes: current agents and future directions. Hasenfuss G; Teerlink JR Eur Heart J; 2011 Aug; 32(15):1838-45. PubMed ID: 21388993 [TBL] [Abstract][Full Text] [Related]
28. [Application of non-glycoside inotropic agents in newborn infants]. Umans-Eckenhausen MA; Terlouw JF; Szatmari A; van den Anker JN Tijdschr Kindergeneeskd; 1993 Feb; 61(1):13-20. PubMed ID: 8493697 [TBL] [Abstract][Full Text] [Related]
29. [Inotropic drugs in treatment of heart failure--advantages and adverse reactions]. Witkowska M Pol Tyg Lek; 1992 Oct 5-12; 47(40-41):936-40. PubMed ID: 1300581 [TBL] [Abstract][Full Text] [Related]
31. Inotropes. Francis GS; Bartos JA; Adatya S J Am Coll Cardiol; 2014 May; 63(20):2069-2078. PubMed ID: 24530672 [TBL] [Abstract][Full Text] [Related]
32. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Shin DD; Brandimarte F; De Luca L; Sabbah HN; Fonarow GC; Filippatos G; Komajda M; Gheorghiade M Am J Cardiol; 2007 Jan; 99(2A):4A-23A. PubMed ID: 17239703 [TBL] [Abstract][Full Text] [Related]
33. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
34. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization. Stevenson LW Circulation; 2003 Jul; 108(3):367-72. PubMed ID: 12876135 [No Abstract] [Full Text] [Related]
35. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704 [TBL] [Abstract][Full Text] [Related]
36. Vitamin C restores the contractile response to dobutamine and improves myocardial efficiency in patients with heart failure after anterior myocardial infarction. Shinke T; Shite J; Takaoka H; Hata K; Inoue N; Yoshikawa R; Matsumoto H; Masai H; Watanabe S; Ozawa T; Otake H; Matsumoto D; Hirata K; Yokoyama M Am Heart J; 2007 Oct; 154(4):645.e1-8. PubMed ID: 17892985 [TBL] [Abstract][Full Text] [Related]
37. [Contractile disorders of the heart and calcium]. Ecker-Schlipf B Med Monatsschr Pharm; 1992 Oct; 15(10):309-11. PubMed ID: 1406441 [No Abstract] [Full Text] [Related]
38. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D; Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942 [TBL] [Abstract][Full Text] [Related]
39. Sodium nitroprusside for advanced low-output heart failure. Mullens W; Abrahams Z; Francis GS; Skouri HN; Starling RC; Young JB; Taylor DO; Tang WH J Am Coll Cardiol; 2008 Jul; 52(3):200-7. PubMed ID: 18617068 [TBL] [Abstract][Full Text] [Related]
40. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Bayram M; De Luca L; Massie MB; Gheorghiade M Am J Cardiol; 2005 Sep; 96(6A):47G-58G. PubMed ID: 16181823 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]